Comparison on the effect of MART-10 and calcitriol on the treatmentof non-small cell lung cancer by determining which one is a morepotent drug in treating non-small cell lung cancer
DOI:
https://doi.org/10.61173/6m86q421Keywords:
MART-10, Calcitriol, non-small cell lung cancer, NSCLC, Cell proliferation, A549 cellAbstract
Non-small cell lung cancer is one of the most common types of lung cancer, with a high mortality rate worldwide.
The current treatment methods have apparent side effects and inevitable drawbacks. A compelling new drug is badly
in need of development. A previous study has reported that calcitriol and MART-10 can effectively block anaplastic
thyroid cancer (ATC) spread. MART -10 is more potent than calcitriol in inhibiting migration and invasion of ATC.
This study investigates the effect of NSCLC using MART-10 and calcitriol and finds out which is more potent, both in
vitro and in vivo. The experiments will use known human non-small cell lung cancer cell lines (A549 cell line) and two
vitamin D compounds: MART-10 and calcitriol and Xenograft mouse system. MTT measures cell proliferation. FACS
measures cell apoptosis for AnnexinV and PI. Measure development in tumor size by mouse xengraft system. A positive
control is taxol, and a negative control is PBS. There are three most possible results: (1) MART-10 and calcitriol can
kill A549 lung cancer cells, and MART-10 reduce the number of A549 lung cancer cells at a lower concentration than
with calcitriol. (2) MART-10 and calcitriol can kill A549 lung cancer cells, and calcitriol reduces the number of A549
lung cancer cells at a lower concentration than with MART-10. (3) MART-10 and calcitriol do not significantly kill
A549 lung cancer cells. The result of the study will provide critical information for the future clinical trial of MART10 and calcitriol in treating NSCLC. It would increase our understanding of the more effective treatment of NSCLC and
improve human health. Future studies should focus on combinations of MART-10 or calcitriol with various anti-cancer
chemotherapy drugs.
References
[1] Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. In Mayo clinic proceedings., 83: 584-594.
[2] Yuan, M., Huang, L. L., Chen, J. H., Wu, J., & Xu, Q. (2019) The emerging treatment landscape of targeted therapy in nonsmall-cell lung cancer. Signal transduction and targeted therapy., 4: 1-14.
[3] Duma, N., Santana-Davila, R., & Molina, J. R. (2019) Non– small cell lung cancer: epidemiology, screening, diagnosis, and treatment. In Mayo Clinic Proceedings., 94: 623-1640.
[4] Deeb K.K, Trump D.L, Johnson C.S. (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer., 7: 684-700.
[5] Chiang K.C, Chen T.C. (2013) The anti-cancer actions of vitamin D. Anticancer Agents Med Chem., 13: 126-39.
[6] Chiang K.C, Yeh C.N, Chen M.F, Chen T.C. (2011) Hepatocellular carcinoma and vitamin D: a review. J Gastroenterol Hepatol. 26: 1597-603.
[7] Chiang K.C, Yeh C.N, Chen T.C. (2011) Vitamin d and pancreatic cancer-an update. Cancers (Basel)., 3: 213-26.
[8] Chiang, K. C., Yeh, T. S., Chen, S. C., Pang, J. H. S., Yeh, C. N., Hsu, J. T., ... & Juang, H. H. (2016) The vitamin D analog, MART-10, attenuates triple negative breast cancer cells metastatic potential. International journal of molecular sciences, 17: 606.
[9] Chiang K.C, Kuo S.F, Chen C.H, Ng S., Lin S.F, Yeh C.N, Chen L.W, Takano M, Chen T.C, Juang H.H, Kittaka A, Lin J.D, Pang J.H. (2015) MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential. Cancer Lett., 369: 76-85.
[10] Townsend M.H, Anderson M.D, Weagel E.G, Velazquez E.J, Weber K.S, Robison R.A. (2017) Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane. Onco Targets Ther., 10: 1921-1932.
[11] Qin, S., Zhao, Y., Lim, G., Lin, H., Zhang, X., & Zhang, X. (2019) Circular RNA PVT1 acts as a competing endogenous RNA for miR-497 in promoting non-small cell lung cancer progression. Biomedicine & pharmacotherapy., 111: 244-250.
[12] Yang, M., et al., (2012) Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells. Onco Targets Ther., 12: 3849-3858.
[13] Li, H., Liu, F., & Qin, W. (2020) Circ_0072083 interference enhances growth-inhibiting effects of cisplatin in non-smallcell lung cancer cells via miR-545-3p/CBLL1 axis. Cancer cell international, 20: 1-13.
[14] Yoshida, S., et al., (2019) Tumor Angiogenic Inhibition Triggered Necrosis (TAITN) in Oral Cancer. Cells., 8: 7.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
